GSK在欧洲获得Exdensur治疗严重哮喘的批准

2026-02-17 22:07

The European Commission has approved GSK's (GSK) Exdensur (depemokimab) for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
Approval was based on the results from two phase 3 programs, SWIFT and ANCHOR, which each met primary or co-primary endpoints.
In the SWIFT-1 and SWIFT-2 studies, there was a 58% and 48% reduction, respectively, in the rate of asthma attacks over one year compared to standard of care alone
Exdensur, an IL-5 antagonist, was approved by the U.S. FDA in December. It is intended to be given via subcutaneous injection every six months.

More on GSK